1365P A prospective, phase II trial of low-dose afatinib monotherapy for patients with EGFR, mutation-positive, non-small cell lung cancer (TORG1632)
Noro, R., Igawa, S., Bessho, A., Hirose, T., Tsuneo, S., Nakashima, M., MInato, K., Seki, N., Tokito, T., Harada, T., Sasada, S., Miyamoto, S., Tanaka, Y., Furuya, N., Kaburagi, T., Hayashi, H., IiharVolume:
31
Journal:
Annals of Oncology
DOI:
10.1016/j.annonc.2020.08.1679
Date:
September, 2020
Fichier:
PDF, 117 KB
2020